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Abstract: Background: Presumed benefits of human breast milk (HM) in avoiding rapid infancy
weight gain and later obesity could relate to its nutrient composition. However, data on
breast milk composition and its relationship with growth are sparse.
Objective: We investigated whether short-chain fatty acids (SCFAs), known to be
present in HM and linked to energy metabolism, are associated with infancy
anthropometrics.
Methods: In a prospective birth cohort, HM hind milk samples were collected from 619
lactating mothers at 4-8 weeks postnatally [median(IQR) age: 33.9(31.3-36.5) y, BMI
(kg/m2): 22.8(20.9-25.2)]. Their offspring, born at 40.1(39.1-41.0) weeks gestation with
weight: 3.56(3.22-3.87) kg and 51% male, were assessed with measurement of infant
weight, length, and skinfold thicknesses at ages 3, 12, and 24 months, and
transformed to age and sex-adjusted z-scores. HM SCFAs were measured by 1H-
nuclear magnetic resonance spectroscopy (NMR) and gas chromatography (GC-MS).
Multivariable linear regression models were conducted to analyse the relationships
between NMR HM SCFAs and infancy growth parameters with adjustment for potential
confounders.
Results: NMR peaks for HM butyrate, acetate, formic acid, but not propionate, were
detected. Butyrate peaks were 17.8% higher in HM from exclusively breastfeeding
mothers than mixed-feeding mothers (p=0.003). HM butyrate peak-values were
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negatively associated with changes in infant weight (standardized B=-0.10, p=0.019)
and BMI (B=-0.10, p=0.018) between 3 and 12 months, and negatively associated with
BMI (B=-0.10, p=0.018) and mean skinfolds thickness (B=-0.10, p=0.049) at age 12
months. HM formic acid peak-values showed a consistent negative association with
infant BMI at all time points (B<=-0.10, P<=0.014) while HM acetate was negatively
associated with skinfolds thickness at 3 months (B=-0.10, p=0.028) and 24 months
(B=-0.10, p=0.036).
Conclusions: These results suggest HM SCFAs play a beneficial role in weight gain
and adiposity during infancy. Further knowledge of HM SCFAs function may inform
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Abstract  1 
Background: Presumed benefits of human milk (HM) in avoiding rapid 2 
infancy weight gain and later obesity could relate to its nutrient composition. 3 
However, data on breast milk composition and its relationship with growth 4 
are sparse. 5 
Objective: We investigated whether short-chain fatty acids (SCFAs), known 6 
to be present in HM and linked to energy metabolism, are associated with 7 
infancy anthropometrics.  8 
Methods: In a prospective birth cohort, HM hind milk samples were collected 9 
from 619 lactating mothers at 4-8 weeks postnatally [median(IQR) age: 10 
33.9(31.3-36.5) y, BMI (kg/m2): 22.8(20.9-25.2)]. Their offspring, born at 11 
40.1(39.1-41.0) weeks gestation with weight: 3.56(3.22-3.87) kg and 51% 12 
male, were assessed with measurement of weight, length, and skinfolds 13 
thickness at ages 3, 12, and 24 months, and transformed to age and sex-14 
adjusted z-scores. HM SCFAs were measured by 1H-nuclear magnetic 15 
resonance spectroscopy (NMR) and gas chromatography (GC-MS). 16 
Multivariable linear regression models were conducted to analyze the 17 
relationships between NMR HM SCFAs and infancy growth parameters with 18 
adjustment for potential confounders. 19 
Results: NMR peaks for HM butyrate, acetate, formic acid, but not 20 
propionate, were detected. Butyrate peaks were 17.8% higher in HM from 21 
exclusively breastfeeding mothers than mixed-feeding mothers (p=0.003). 22 
HM butyrate peak-values were negatively associated with changes in infant 23 
weight (standardized B=-0.10, p=0.019) and BMI (B=-0.10, p=0.018) 24 





p=0.018) and mean skinfolds thickness (B=-0.10, p=0.049) at age 12 26 
months. HM formic acid peak-values showed a consistent negative 27 
association with infant BMI at all time points (B<=-0.10, P<=0.014) while HM 28 
acetate was negatively associated with skinfolds thickness at 3 months (B=-29 
0.10, p=0.028) and 24 months (B=-0.10, p=0.036).  30 
Conclusions: These results suggest HM SCFAs play a beneficial role in 31 
weight gain and adiposity during infancy. Further knowledge of HM SCFAs 32 
function may inform future strategies to support healthy growth.  33 
Keywords: breast milk, short chain fatty acids, lipids, nutrition, weight, 34 






Early postnatal nutrition is critical for infant optimal growth and associated 37 
with long-term health outcomes1. The type of infant milk feeding, as well as 38 
specific dietary compositions and volume of intake, may be important factors. 39 
 40 
Human milk (HM) intake has been associated with beneficial immunological 41 
responses, infancy growth patterns and potential later obesity risk reduction2–42 
4. A diverse range of bioactive components in HM could contribute to these 43 
protective effects and may be associated with different patterns of weight and 44 
adiposity gain during infancy5. Nevertheless, data on HM composition and 45 
relationships with growth are limited.  46 
 47 
Fat (triglycerides and fatty acids) is an important nutritional constituent of 48 
HM. It derives either from the maternal circulation or is synthesized in the 49 
mammary glands6–8. We recently reported that the fat % energy in HM is 50 
inversely associated with subsequent weight gain and adiposity during 51 
infancy, suggesting functional implications of HM macronutrient contents9. 52 
The quality and quantity of fat and fatty acid constituents, such as short-chain 53 
fatty acids (SCFAs: acetate, butyrate, formate, propionate, and valerate) 54 
could be relevant to infant growth. SCFAs as well as being a constituent of 55 
foods, are synthesized in the gut by an anaerobic microbiota during 56 
fermentation of HM oligosaccharides. Butyrate is frequently measured in 57 
faeces, but this is only a small proportion of what is being produced in the 58 
gut. Its circulating concentration is affected by liver and intestinal epithelial 59 





is present in significant quantities in bovine milk11, however, its origin, form, 61 
concentration, and biological function in HM deserves further study12. 62 
Butyrate, a 4-C fatty acid, has previously been detected in HM13,14, but it is 63 
unclear if it is esterified to triglycerides (TGs) or exists as free butyrate. 64 
SCFAs are highly volatile and such data are limited by a lack of consensus 65 
on assay methods, HM concentrations, and functional relevance.  66 
 67 
Preclinical studies show that prebiotics and/or SCFAs intake is associated 68 
with lower body weight, and suggest that SCFAs may have a complex role in 69 
energy metabolism. For example, acetate intake has been associated with 70 
lower body weight in animals15–21. In high-fat fed mice, butyrate intake 71 
reportedly attenuates obesity-associated inflammation and insulin 72 
resistance22, possibly by activating the SCFAs receptor, GPR4323. 73 
 74 
Here, we aimed to confirm the presence of SCFAs in HM and test the 75 
hypothesis that HM SCFAs concentrations are associated with growth and 76 





Subjects and Methods 78 
Study Design: The Cambridge Baby Growth Study (CBGS: 2001-2009) is a 79 
prospective birth cohort, set up to investigate antenatal and early postnatal 80 
determinants of infancy growth, as described previously24. In brief, women 81 
were recruited in early pregnancy from a single hospital in Cambridge, UK, 82 
and followed through pregnancy and postnatally. The cohort included 1585 83 
singleton, late preterm or full-term born (gestational age ≥ 36 weeks) infants 84 
with measurements at birth; 64% of mothers exclusively breastfed their 85 
infants at 8 weeks postnatally. This analysis is based on a subset of 619 86 
mother-infant dyads, where a HM sample was collected. All mothers gave 87 
informed written consent and the study was approved by the Cambridge local 88 
research ethics committee. 89 
 90 
Anthropometry: Trained nurses measured infant weight, length and skinfolds 91 
thickness in the first 8 days of life, and then at ages 3, 12, and 24 months. 92 
Weight was measured to the nearest 1g (Seca 757 electronic baby scale). 93 
Supine length was measured to the nearest 0.1cm (Infantometer SECA 416), 94 
and BMI was then calculated. Skinfolds thickness were measured in triplicate 95 
at 4 body sites (triceps, subscapular, flank, quadriceps) on the left side of the 96 
body (Tanner/Whitehouse Skinfold Caliper, Holtain Ltd). 97 
 98 
HM collection: Women were asked to hand express hindmilk into low binding 99 
glass bottles, after feeding their infant, from the breast that they had last 100 
used for feeding. In order to reduce within-day and day-to-day variations and 101 





over a two week period between 4-8 weeks postnatally in order to collect a 103 
total pooled sample of 100 mL hindmilk. HM samples were kept frozen to 104 
prevent volatilization of SCFAs. All samples were processed together at a 105 
single time point, with the oldest samples being stored continuously at -200C 106 
for 16 years. Each pooled HM sample was mixed thoroughly before analysis. 107 
Infant feeding (exclusive breast- vs. mixed-feeding) was reported by 108 
questionnaire at 3 months of age, with questions about current feeding, and 109 
age at starting infant formula milk. Infants were categorized as either 110 
exclusively breast- or mixed-fed at 8 weeks of age, at the time of HM 111 
sampling. 112 
 113 
HM assays:  SCFAs concentrations were measured in homogenized HM 114 
samples using 1H-Nuclear magnetic resonance (NMR) spectra and Gas 115 
chromatography (GC-MS).  116 
 117 
1H-NMR analyses: To determine SCFAs composition with NMR, 400 118 
microliters (µL) of a homogenized HM sample was mixed with 400 µL CDC3 119 
solvent for 10 minutes and then centrifuged [Eppendorf centrifuge 5424 120 
(Eppendorf AG, Hamburg, Germany)] for 30 minutes at 9,500 g. The polar 121 
fraction was then used to measure total SCFAs content as NMR spectra 122 
peak heights as described by Prentice et al9.  123 
 124 
To determine the contribution of HM TGs to total butyrate NMR peak-value, 125 
HM samples were exposed to lipase (Candida rugose, Sigma L8525, 126 





stock (3 mg/mL) was added and incubated for 17 hours at 370C. After cooling 128 
to 00C, samples were prepared for NMR. One sample was spiked with 129 
tributyrin (Sigma T8626) as a positive control. 130 
 131 
GC-MS free butyrate measurements: One mL HM samples were preheated 132 
in 10 mL vials sealed with silicon/Teflon septa and magnetic caps for 1 133 
minute at 600C. Volatile metabolites were extracted from the headspace for 5 134 
minutes with a 75 μm PDMS-carboxen SPME fibre (Supelco, Bellefonte, PA, 135 
USA) using the combiPAL autosampler (CTC Analytics AG, Switzerland). 136 
The volatile metabolites were thermally desorbed from the fibre by heating it 137 
in a Best PTV injector with an empty liner for 5 min at 2500C. The fibre was 138 
subsequently cleaned for 10 min at 2900C. A vial with air was used as blank. 139 
GC separation of the volatile components was performed on a Finnigan 140 
Trace GC gas chromatograph (ThermoFinnigan, San Jose, CA, USA) 141 
coupled to a Finnigan DSQ mass spectrometer (ThermoFinnigan, San Jose, 142 
CA, USA), using a polar Stabilwax-DA column of 30 m length, 0.32 mm i.d., 143 
and 0.32 mm film thickness (Restek Bellefonte, PA, USA). The oven 144 
temperature was held at 400C for 2 minutes, raised to 2200C at 145 
150C/minutes, followed by 1 minute holding. Helium was used as the carrier 146 
gas at a flow rate of 1.5 mL/minute (Stabilwax-DA column). The MS interface 147 
and the ion source were kept at 2500C. Acquisition was performed in electron 148 
impact mode (70 eV) with 2 scans/s; the mass range used was m/z 33-250.  149 
 150 
GC-MS chromatograms were analyzed for peak identification using AMDIS 151 





based on matching mass spectra and retention time with pure standards. 153 
Volatile metabolites were integrated using the XCalibur software package 154 
(ThermoFinnigan, San Jose, CA, USA). The peak area (corrected for blank if 155 
necessary) in arbitrary units was used for statistical analysis. Absolute 156 
quantification was undertaken using standard addition of butyrate to milk 157 
samples. 158 
 159 
Anthropometry variables: Age and sex-appropriate standard deviation scores 160 
(SDS) were calculated for infant weight, length, and BMI, adjusting for 161 
gestational age at birth, by comparison to the UK 1990 growth reference25 162 
using LMS Pro software26. An internal SDS was calculated for each of the 163 
four skinfolds thickness, adjusting for age, and the mean of the four skinfolds 164 
thickness SDS was used as an estimate of total adiposity.  165 
 166 
Statistics: NMR SCFAs concentrations were square-root transformed to 167 
normalize their distributions; the SCFAs content was calculated from the sum 168 
of the individual NMR SCFAs peak-values; GC-MS butyrate concentrations 169 
were similarly log-transformed. Spearman rank-correlation was used to 170 
assess the relationship between the NMR (total) butyrate peak 171 
concentrations with the GC-MS (free) butyrate concentrations. Relationships 172 
between NMR HM SCFAs and infancy growth parameters were tested in 173 
multivariable linear regression models, including the following covariates: 174 
birth weight, gestational age, infant sex, infant milk feeding, and HM storage 175 
time. To assess associations between HM butyrate peak-values and infant 176 





was entered as an additional covariate to the regression models. Therefore, 178 
we used a residual nutrient method9: HM butyrate peak-values were 179 
regressed against HM TGs concentrations, and the resulting standardized 180 
residuals were tested for association with infant growth. Analyses were 181 
performed using SPSS version 21, and statistical significance indicated by p-182 
value <0.05. 183 
 184 
Results 185 
As many as 619 mothers of singleton, term or late preterm infants provided a 186 
HM sample (453 exclusively breastfeeding at 8 weeks postnatally, 124 187 
mixed-feeding, 42 unknown feeding type). There was no difference between 188 
this subgroup and all breastfeeding mother-infant pairs in the whole CBGS 189 
cohort with respect to gestational age, maternal age, pre-pregnancy BMI, 190 
primiparity, ethnicity, infant size at birth or growth to 12 months of age9. 191 
(Table 1). 192 
 193 
HM SCFAs content 194 
For the 619 HM samples collected at age 4-8 weeks, NMR peaks were 195 
detected for butyrate, acetate, and formic acid, but not propionate (Table 2). 196 
HM volatile phase free butyrate was also detected by GC-MS (N=102), at 197 
concentrations ranging from 0 to 3.5 mg per 100 ml. NMR (total) butyrate 198 
peak concentrations were moderately well correlated with GC-MS (free) 199 






Modest inter-correlations were detected between NMR HM SCFAs peak-202 
values. Butyrate peak-values were weakly positively correlated with acetate 203 
peak-values (rs=0.10, p=0.010) and weakly negatively correlated with formic 204 
acid peak-values (rs= -0.09, p=0.021); acetate was weakly positively 205 
correlated with formic acid (rs=0.10, p=0.016). HM total fat (TGs) 206 
concentrations were positively correlated with NMR butyrate peak-values 207 
(rs=0.67, p<0.0005; Figure 1) and were weakly positively correlated with 208 
acetate peak-values (rs=0.12, p=0.003), but were not correlated with formic 209 
acid peak-values (rs=0.00, p=0.9). 210 
 211 
Lipase treatment did not change NMR butyrate peak-values in CBGS HM 212 
samples but increased these peak-values in positive control HM samples 213 
spiked with tributyrin (data not shown), indicating that degradation of TGs in 214 
HM samples post-collection does not contribute to total butyrate content.  215 
 216 
Correlates of HM SCFAs content 217 
HM SCFAs content (butyrate, acetate, or formic acid) was not associated 218 
with maternal BMI, parity, mode of delivery, socioeconomic status, 219 
gestational age, infant birth weight or sex. HM butyrate peak-values modestly 220 
declined with longer HM storage time (rs= -0.13, p=0.001), whereas acetate 221 
and formic acid peak-values increased. Butyrate peak-values were higher in 222 
HM from exclusively breastfeeding mothers compared to those mixed-223 
feeding: median (IQR) peak-value 2.81 (2.07) vs. 2.31 (2.11) (p=0.001), but 224 
acetate and formic acid peak-values did not differ (not shown). Subsequent 225 






HM SCFAs associations with infancy growth 228 
There were no associations between any SCFAs content and infant size at 229 
birth, or with infant length at any age. HM (NMR) butyrate peak 230 
concentrations were negatively associated with changes in infant weight 231 
(standardized B=-0.10, p=0.019) and BMI (B=-0.10, p=0.018) between ages 232 
3 to 12 months, and negatively associated with BMI (B=-0.10, p=0.018) and 233 
mean skinfolds thickness (B=-0.10, p=0.049) at age 12 months (Table 2). 234 
These apparent effects on infant adiposity were attenuated by age 24 235 
months as a consequence of positive associations between HM butyrate 236 
peak-values and changes in infant BMI and skinfolds thickness between 12 237 
to 24 months (Table 2). 238 
 239 
HM formic acid showed a consistent negative association with infant BMI at 240 
all time points (3, 12 and 24 months: all B<=-0.10, P<=0.014) while HM 241 
acetate was negatively associated with skinfolds thickness at ages 3 months 242 
(B=-0.10, p=0.028) and 24 months (B=-0.10, p=0.036) (Table 2).  243 
Adjustments for HM TGs concentrations attenuated the above associations 244 
with HM butyrate peak concentrations, but the associations with HM formic 245 
acid and HM acetate largely persisted (Table 2).  246 
 247 
Discussion 248 
This study provides evidence that the SCFAs, butyrate, formic acid, and 249 
acetate, are detectable in HM and show largely negative associations with 250 





age 3-12 months and were predictably less evident when mixed feeding had 252 
been introduced by age 12-24 months. Thus our data provide preliminary 253 
data that breast milk SCFAs concentrations may provide some early 254 
protection against excess weight gain. We accept that this interpretation is 255 
based on the assumption that lower weight gain and reduced fat accretion is 256 
beneficial but this is the prevailing assumption concerning the protective 257 
effects of breast milk feeding on the risk of obesity. These associations with 258 
infancy growth have not been previously reported, likely due to the lack of 259 
large mother-infant cohort studies with HM samples and limitations in SCFAs 260 
measurements.  261 
 262 
However, our observations are supported by experimental data from animal 263 
models that identified a role for SCFAs including butyrate, in regulating lipid 264 
metabolism and body weight gain. Dietary butyrate supplementation 265 
reversed high-fat diet-induced weight gain and detrimental changes in fat 266 
tissue and metabolic outcomes27, such as obesity-associated inflammation 267 
and insulin resistance22,28. The resistance to obesity development by butyrate 268 
supplementation may be explained in part by increased thermogenesis and 269 
energy expenditure16 resulting from activation of brown adipose tissue 270 
through increased sympathetic activity29. 271 
  272 
In addition to oral dietary butyrate administration, the endogenous production 273 
of SCFAs resulting from microbial carbohydrate fermentation has been 274 
shown to affect peripheral tissues, by acting as signal transduction molecules 275 





modulators of gene expression via inhibition of histone deacetylase 277 
(HDAC)21. 278 
 279 
In adipose tissue, butyrate affects adipogenesis and fat cell metabolism, 280 
either directly or indirectly through anti-inflammatory mechanisms. This would 281 
suggest a role for butyrate in metabolic processes, healthy weight 282 
development, and mitigating inflammation in adipose tissue, thereby 283 
potentially reducing the risk of obesity30,31. The observation that butyrate acts 284 
as an epigenetic regulator32 may indicate a role for HM derived butyrate in 285 
the epigenetic regulation of adipose tissue function, hence affecting the 286 
programming of healthy weight development in offspring.  Alternatively it has 287 
been proposed that acetate may have a direct role in regulating central 288 
appetite regulation33. 289 
 290 
Thus, although the exact mechanisms remain to be elucidated, in addition to 291 
endogenously produced butyrate, HM derived butyrate may contribute to the 292 
regulation of adiposity and its related metabolic changes. Based on the 293 
results from the current study HM butyrate may stimulate normal infant 294 
adiposity and metabolism, thus supporting healthy weight development in 295 
early life. Interestingly directly after birth, endogenous SCFAs and butyrate 296 
production in the infant gut is relatively low which gradually increases over 297 
time while the microbiota matures10. It is thus interestingly to speculate that 298 
HM may provide an initial supply of butyrate to the newborn while 299 






The exact source of HM butyrate remains to be elucidated. Our current 302 
findings suggest that HM butyrate exists largely as a free SCFA, as the 303 
addition of enzymatic lipase to samples ex vivo did not increase the HM 304 
butyrate peaks. However, we cannot exclude the contribution of glycerides 305 
as lipases in HM are expressed in significant amounts and contribute to lipid 306 
digestion and overall fatty acid bioavailability in the developing infant34. 307 
Furthermore, HM butyrate could derive from synthesis by microbiota, which 308 
is known to be resident in HM35.  309 
 310 
Unfortunately, HM volume intakes were not assessed in our study and 311 
therefore we cannot assess whether the associations observed with HM 312 
SCFAs contents were mediated by SCFAs rather than total intakes. Mothers 313 
were asked to pool, over a period of 2 weeks, their collected expressed hind 314 
milk samples and information on the timings of milk collection was not 315 
recorded. Future studies should include measurements of HM intakes and 316 
assessment of the feasibility of using lipase inhibitors to reduce hydrolysis of 317 
TGs to better understand the origin of SCFAs. The observation that butyrate 318 
levels were higher in the milk of mothers who exclusively breastfed is 319 
interesting but unexplained although it may relate to the length of feeds as 320 
we know TGs levels are increased in hind milk. Repeated longitudinal HM 321 
collections and assessment of the microbiome will provide data necessary to 322 
understand the relationships between HM SCFAs and infant growth. Such 323 
understanding may help to elucidate the potential beneficial properties of HM 324 
in supporting optimal growth and adiposity during infancy, particularly in 325 






Conclusion:  HM SCFAs, mainly butyrate measured as free acid in hind 328 
milk, may play a beneficial role in weight gain and adiposity during infancy. 329 
Further knowledge of HM and exploration of HM SCFAs origin may inform 330 
future strategies to support healthy growth. 331 
 332 
Acknowledgements: We acknowledge the CBGS research nurses Suzanne 333 
Smith, Anne-Marie Wardell & Karen Forbes. We thank all the families who 334 
contributed to the study, the staff at the Cambridge NIHR/Wellcome Trust 335 
Clinical Research Facility, the NIHR Cambridge Comprehensive Biomedical 336 
Research Centre, and the midwives at the Rosie Maternity Hospital, 337 
Cambridge, UK. We acknowledge Kelly Dingess for her support with butyrate 338 
measurements. 339 
 340 
Authors’ contributions:  341 
The authors’ responsibilities were as follows: PMP, CLA, KKO, DBD: 342 
designed the project; PMP, JV, KH, AK: conducted the research; PMP, MHS, 343 
JV, KKO: performed statistical analyses; PMP, MHS, TTL, AK, LO, CP, JV, 344 
EAFT, KKO, DBD: wrote the manuscript; DBD had primary responsibility for 345 
final content; and all authors: critically revised the manuscript for important 346 






1.  Lanigan J, Singhal A. Early nutrition and long-term health: A practical approach. Proc 
Nutr Soc. 2009;68:422-9. doi:10.1017/S002966510999019X. 
2.  Ziegler EE. Growth of Breast-Fed and Formula-Fed Infants. Nestlé Nutr Work Ser 
Pediatr Progr. 2006;58:51-63. 
3.  Stein AD, Barros FC, Bhargava SK, Hao W, Horta BL, Lee N, Kuzawa CW, Martorell 
R, Ramji S, Stein A, et al. Birth status, child growth, and adult outcomes in low- and 
middle-income countries. J Pediatr. 2013;163:1740-6.e4. 
doi:10.1016/j.jpeds.2013.08.012. 
4.  Ong KK, Emmett P, Northstone K, Golding J, Rogers I, Ness AR, Wells JC, Dunger 
DB. Infancy weight gain predicts childhood body fat and age at menarche in girls. J 
Clin Endocrinol Metab. 2009;94:1527-32. doi:10.1210/jc.2008-2489. 
5.  Ballard, O. Morrow A. Human milk composition: nutrients and bioactive factors. Pediatr 
Clin North Am. 2013;60:49-74. doi:10.1016/j.pcl.2012.10.002. 
6.  Jensen RG, Lammi-Keefe CJ, Ferris AM, Jackson MB, Couch SC, Capacchione CM, 
Ahn HS, Murtaugh M. Human milk total lipid and cholesterol are dependent on interval 
of sampling during 24 hours. J Pediatr Gastroenterol Nutr. 1995;20:91-4. 
7.  Hamosh M, Bitman J. Human milk in disease: Lipid Composition. Lipids. 1992;27:848-
57. doi:10.1007/BF02535863. 
8.  Hester SN, Hustead DS, MacKey AD, Singhal A, Marriage BJ. Is the macronutrient 
intake of formula-fed infants greater than breast-fed infants in early infancy? J Nutr 
Metab. 2012;2012. doi:10.1155/2012/891201. 
9.  Prentice P, Ong KK, Schoemaker MH, van Tol EAF, Vervoort J, Hughes IA, Acerini 
CL, Dunger DB. Breast milk nutrient content and infancy growth. Acta Paediatr. 
2016;105:641-7. doi:10.1111/apa.13362. 
10.  Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, Nauta 
A, Raes J, van Tol EAF, Tuohy KM. Towards microbial fermentation metabolites as 






11.  McNabney SM, Henagan TM. Short chain fatty acids in the colon and peripheral 
tissues: A focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients. 
2017;9:1-28. doi:10.3390/nu9121348. 
12.  Walker WA, Shuba Iyengar R. Breastmilk, microbiota and intestinal immune 
homeostasis. Pediatr Res. 2014;77:1-9. doi:10.1038/pr.2014.160. 
13.  Precht D, Molkentin J. C18:1, C18:2 trans and cis fatty acid isomers including 
conjugated cis Δ9, trans Δ11 linoleic acid (CLA) as well as total fat composition of 
German human milk lipids. Nahrung. 1999;43:233-44. 
14.  Li G, Yao W, Jiang H. Short-chain fatty acids enhance adipocyte differentiation in the 
stromal vascular fraction of porcine adipose tissue. J Nutr. 2014;144:1887-95. 
doi:10.3945/jn.114.198531. 
15.  Roy CC, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? 
Nutr Clin Pract. 2006;21:351-66. doi:10.1177/0115426506021004351. 
16.  Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate 
improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 
2009;58:1509-17. doi:10.2337/db08-1637. 
17.  Lin HV, Frassetto A, Kowalik EJ, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto 
D, Yao X, Forrest G, et al. Butyrate and propionate protect against diet-induced 
obesity and regulate gut hormones via free fatty acid receptor 3-independent 
mechanisms. PLoS One. 2012;7:1-9. doi:10.1371/journal.pone.0035240. 
18.  Carvalho BM, Jose M, Saad A. Influence of gut microbiota on subclinical inflammation 
and insulin resistance. Mediators Inflamm. 2013;2013:1-13. 
19.  Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a 
probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 
2013;288:25088-97. doi:10.1074/jbc.M113.452516. 
20.  den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM. The 





energy metabolism. J Lipid Res. 2013;54:2325-40. doi:10.1194/jlr.R036012. 
21.  Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial 
metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 
2015;7:2839-49. doi:10.3390/nu7042839. 
22.  Vinolo MAR, Rodrigues HG, Festuccia WT, Crisma AR, Alves VS, Martins AR, Amaral 
CL, Fiamoncini J, Hirabara SM, Sato FT, et al. Tributyrin attenuates obesity-
associated inflammation and insulin resistance in high-fat-fed mice. Am J Physiol 
Endocrinol Metab. 2012;303:E272-82. doi:10.1152/ajpendo.00053.2012. 
23.  Kimura I, Inoue D, Hirano K, Tsujimoto G. The SCFA receptor GPR43 and energy 
metabolism. Front Endocrinol (Lausanne). 2014;5:1-3. doi:10.3389/fendo.2014.00085. 
24.  Prentice P, Acerini CL, Eleftheriou A, Hughes IA, Ong KK, Dunger DB. Cohort profile: 
The Cambridge Baby Growth Study (CBGS). Int J Epidemiol. 2016;45:35-35g. 
doi:10.1093/ije/dyv318. 
25.  Freeman J V., Cole TJ, Chinn S, Jones PRM, White EM, Preece MA. Cross sectional 
stature and weight reference curves for the UK, 1990. Arch Dis Child. 1995;73:17-24. 
doi:10.1136/adc.73.1.17. 
26.  Pan H, Cole T. LMSgrowth, a Microsoft Excel add-in to access growth references 
based on the LMS method. 2012. http://www.healthforallchildren.co.uk/. 
27.  Arnoldussen IAC, Wiesmann M, Pelgrim CE, Wielemaker EM, van Duyvenvoorde W, 
Amaral-Santos PL, Verschuren L, Keijser BJF, Heerschap A, Kleemann R, et al. 
Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-
adult obese mice. Int J Obes. 2017;41:935-44. doi:10.1038/ijo.2017.52. 
28.  Raso GM, Simeoli R, Russo R, Iacono A, Santoro A, Paciello O, Ferrante MC, Canani 
RB, Calignano A, Meli R. Effects of sodium butyrate and its synthetic amide derivative 
on liver inflammation and glucose tolerance in an animal model of steatosis induced 
by high fat diet. PLoS One. 2013;8:1-13. doi:10.1371/journal.pone.0068626. 
29.  Li Z, Yi CX, Katiraei S, Kooijman S, Zhou E, Chung CK, Gao Y, van den Heuvel JK, 





tissue via the gut-brain neural circuit. Gut. 2018;67:1269-1279. doi:10.1136/gutjnl-
2017-314050. 
30.  Meijer K, De Vos P, Priebe MG. Butyrate and other short-chain fatty acids as 
modulators of immunity: What relevance for health? Curr Opin Clin Nutr Metab Care. 
2010;13:715-721. doi:10.1097/MCO.0b013e32833eebe5. 
31.  Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota 
and obesity-related metabolic diseases? Obes Rev. 2013;14:950-959. 
doi:10.1111/obr.12068. 
32.  Davie J. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133:2485S-
2493S. 
33.  Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, Anastasovska J, 
Ghourab S, Hankir M, Zhang S, et al. The short-chain fatty acid acetate reduces 
appetite via a central homeostatic mechanism. Nat Commun. 2014;5:1-11. 
doi:10.1038/ncomms4611. 
34.  Lindquist S, Hernell O. Lipid digestion and absorption in early life: An update. Curr 
Opin Clin Nutr Metab Care. 2010;13:314-20. doi:10.1097/MCO.0b013e328337bbf0. 
35.  McGuire MK, McGuire MA. Got bacteria? The astounding, yet not-so-surprising, 









TABLE 1 Participant characteristics in the current analysis (who provided a human milk 
sample) and wider Cambridge Baby Growth Study cohort1 
 Current sample: with HM 
sample 
All breast- or mixed-
fed 
Demographics   
Participants, n 619 924 
Gestational age, weeks 40.1 (39.1-41.0) 40.0 (39.1-41.0) 
Maternal age, years 33.9 (31.1-36.5) 34.0 (31.2-36.5) 
Maternal BMI, kg/m2 22.8 (20.9-25.2) 22.7 (20.8-25.2) 
Index of deprivation 9.0 (6.9-9.0) 9.0 (6.8-9.0) 
Maternal primiparity, n(%) 266(43) 388(42)  
White Caucasian, n(%)  594(96) 887(96) 
Infant male sex, n(%) 316(51) 471(51) 
Exclusive breast-feeding, n(%) 452(73) 712(77) 
Infant growth    
Birth   
Weight, kg 3.56 (3.22-3.87) 3.55 (3.22-3.85) 
Length, cm 51.5 (50.0-53.5) 51.5 (50.0-53.3) 
Mean skinfolds thickness, mm 6.2 (5.3-7.4) 6.1 (5.2-7.3) 
BMI, kg/m2 13.3 (12.2-14.3) 13.3 (12.2-14.2) 
3 months   
Weight, kg 6.10 (5.60-6.64)  6.09 (5.59-6.62)  
Length, cm 61.2 (59.4-63.0) 61.2 (59.5-63.0)  
Mean skinfolds thickness, mm 10.8 (9.4-11.9) 10.7 (9.4-11.9)  
BMI, kg/m2 16.3 (15.4-17.2) 16.2 (15.3-17.2) 
12 months   
Weight, kg 9.85 (9.10-10.60)  9.88 (9.15-10.60)  
Length, cm 75.8 (74.0-77.7) 75.6 (73.9-77.7)  
Mean skinfolds thickness, mm 11.0 (9.8-12.5)  11.0 (9.7-12.4)  
BMI, kg/m2 17.1 (16.2-18.0) 17.1 (16.3-18.1) 






TABLE 2 HM SCFAs peak-values measured by NMR and their associations with infant 
growth from 3-24 mo1  
 SCFAs (ranges) 
Associations with infant 
growth 
Butyrate (0-0.4 mM) Formate (0.1-7.5 mM) Acetate (0.1-8.5 mM) 
 B P B P B P 
Weight SDS        
3 mo   0.03 0.4 -0.04 0.2 -0.04 0.3 
12 mo -0.03 0.4 -0.08 0.054 -0.02 0.6 
24 mo 0.03 0.5 -0.12 0.005* -0.05 0.3 
 Weight SDS       
3-12 mo -0.10 0.019 -0.05 0.3  0.02 0.7 
12-24 mo 0.09 0.04 -0.03 0.5 -0.05 0.3 
BMI SDS       
3 mo -0.01 0.7 -0.10 0.0112 -0.05 0.3 
12 mo -0.10 0.018 -0.11 0.0142  0.00 0.9 
24 mo 0.02 0.7 -0.12 0.0072 0.02 0.6 
 BMI SDS       
3-12 mo -0.11 0.010 0.01 0.9  0.04 0.4 
12-24 mo 0.13 0.005 0.01 0.8 -0.01 0.8 
Mean skinfolds SDS       
3 mo -0.02 0.7 -0.02 0.6 -0.10 0.0282 
12 mo -0.08 0.049 -0.03 0.5 -0.05 0.3 
24 mo 0.01 0.8 -0.10 0.0212 -0.10 0.0363 
 Skinfolds thickness SDS       
3-12 mo -0.08 0.057 -0.01 0.9  0.06 0.2 
12-24 mo  0.09 0.047 -0.07 0.14 -0.09 0.071 
1Values are standardized regression coefficients (p-values) adjusted for exclusive breast- vs. 
mixed feeding at 8 weeks, sex, GA, birthweight, duration of sample storage. SCFA 
concentrations were square-root transformed. 
2P<0.05 following additional adjustment for HM TGs concentrations 








Figure 1: Scatterplot of HM butyrate peak values measured by NMR versus concentrations 
measured by GC-MS (n=102) (A) and HM TGs concentrations (B) (n=619).  




Figure 2: Changes from 3-12 mo in infants’ body weight SDS (A), BMI SDS (B), and 
skinfolds SDS by quintiles of HM butyrate peak values measured by NMR at 4-8 wk of age. 
Values are group means and 95% CIs. 
BMI, body mass index; CIs, confidence intervals; HM, human breast milk; NMR, nuclear 
magnetic resonance; SDS, standard deviation score. 
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